BioSight
Back
Viking Therapeutics, Inc. logo

VKTX

NASDAQSAN DIEGO, CA
Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, primarily using peptide agonist modalities. The company's lead program is VK2735, a dual GLP-1 and GIP receptor agonist available in oral and subcutaneous formulations currently in Phase 2 development for obesity and other metabolic disorders, with the Phase 2 VENTURE study evaluating weekly subcutaneous dosing in obese and overweight patients.

$31.18+8.00%1Y
VKTX · daily close · illustrative · 0 catalysts marked
1Y high$42.091Y low$23.09range$19.00(82%)past catalysts

Pipeline1

VK2735
Phase 3Weight Loss
Unknownnot specified in filing
small-molecule

Catalyst Calendar2

JUL
2027
382d
ReadoutVK2735
“A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or Overweight — primary completion 2027-07-01”
CT.gov ↗
Past (1)
AUG 19
2025
ReadoutVK2735
“On August 19, 2025, Viking Therapeutics, Inc. issued a press release announcing top-line results from the Company's Phase 2 clinical trial of the oral tablet formulation of VK2735.”
8-K ↗

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.